The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Practical reference · maintained document

Access notes: Netherlands

Maintainers: impurity_table, q.zhao_qa, mira.patel Last updated 29 December 2025 Next review due 9 August 2026 343 words · 6 revisions
Sourced from a discussion. This document was promoted out of Coming back to: Cross-border purchase rules within the EU, in European Union. That topic links back here, and corrections raised there flow into this page.

Regulator, prescription status, reimbursement position and practical access route for Netherlands. Every claim dated, because this changes constantly.

Scope and expiry

Practical access notes for Netherlands: who regulates, what prescription status applies, how reimbursement is decided, and what route people actually use.

This page expires. Access conditions in this field have changed several times a year since 2023. The review date at the top of this page is the date it was last checked against primary sources. If you are making a decision, read the current official document rather than this page.

Regulatory and prescription position

The College ter Beoordeling van Geneesmiddelen implements the EU framework. Prescription is required and general practitioners are the usual first point of contact.

Coverage and cost

Basic insurance coverage for weight management has been conditional on specific criteria including participation in a structured lifestyle programme. Meeting the criteria is generally the determining factor rather than the drug itself.

Dutch pharmacy practice is conservative about irregular prescriptions and the pharmacist will ask questions. That is a feature rather than an obstacle.

The route people actually use

In practice the access question in Netherlands resolves into three sub-questions: whether a prescription can be obtained, whether it will be funded, and whether the product is currently in supply. Those have different answers and different remedies, and conflating them is the commonest reason a member gets stuck.

If funding is the obstacle, the appeal discussion in Access is more useful than another consultation. If supply is the obstacle, the national shortage register — where one exists — is the only source worth reading.

What this page will not help with

This page does not describe how to obtain unlicensed material, and this community does not assist with that. It also does not tell you whether something is legal for you to possess, because that depends on facts about you that a documentation page cannot know.

Research-use-only material is not a licensed medicine in Netherlands or anywhere else we are aware of.

Contributing

Regional pages are maintained by members in the region. If you can confirm or contradict anything here from a primary source, post in the regional category with the source and the date. An undated claim in this area is worse than no claim, and we will ask for the date.

Revision history

2025-12-29sourced_claimsAdded the table of acceptance criteria requested in doc review.
2025-11-05r.venkatesanAnnual review: checked every figure against its source. Two rounded values tightened.
2025-10-10mira.patelAdded cross-references to the two topics that most often ask this question.
2025-07-04q.zhao_qaPlain-language pass on the opening section after feedback from a newcomer.
2025-04-25aliquot_lineRestructured into shorter sections so the outline navigation is usable.
2025-03-15ms_hollowayInitial promotion from the source topic. Structure taken from the marked solution.

Every edit to a maintained document records its author and a note explaining the change. An edit without a note may be reverted by any wiki editor under R9, and the revert is logged. Disagreements about content belong on the source topic rather than in the revision history (R10).

Related documents

  • Access notes: GermanyRegulator, prescription status, reimbursement position and practical access route for Germany. Every claim dated,…
  • Access notes: FranceRegulator, prescription status, reimbursement position and practical access route for France. Every claim dated,…
  • Access notes: SpainRegulator, prescription status, reimbursement position and practical access route for Spain. Every claim dated,…
  • Access notes: ItalyRegulator, prescription status, reimbursement position and practical access route for Italy. Every claim dated,…
  • Access notes: PolandRegulator, prescription status, reimbursement position and practical access route for Poland. Every claim dated,…